Abstract 376P
Background
Optimal treatment outcomes in breast cancer heavily rely on patient adherence to oral anticancer medications (OAMs). This study investigates the differences in adherence rates between metastatic and non-metastatic breast cancer patients using a comprehensive dual-method approach.
Methods
In this cross-sectional study at the National Cancer Institute, Cairo University, 500 breast cancer patients were categorized into metastatic (45.6%) and non-metastatic (54.4%) groups. Adherence was measured using the Morisky Medication Adherence Scale (MMAS-8) and the Medication Possession Ratio (MPR), with nonadherence defined as an MMAS-8 score < 8 or an MPR < 80 %. Data collection was augmented by patient interviews and examination of outpatient pharmacy dispensing records.
Results
Adherence rates were 46.4% as per MMAS-8 and 71% according to MPR. Specifically, in the non-metastatic group, MMAS-8 revealed a 28.3% adherence rate, while MPR showed 75.4%. Metastatic patients displayed significantly higher adherence (p<0.001). There was a notable inverse correlation between adherence and the severity of side effects like musculoskeletal pain, neurological symptoms, fatigue, and hot flushes (p<0.001). Additionally, adherence varied with treatment duration, with shorter periods associated with better adherence.
Conclusions
The study confirms that adherence to OAMs is significantly affected by both the metastatic status and the severity of side effects. It highlights the urgent need for enhanced educational and management strategies tailored to the specific challenges faced by breast cancer patients, especially those dealing with severe side effects. Ongoing research should focus on developing and testing targeted interventions to improve adherence in these patient groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Cancer Institute, Cairo University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
385P - A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Presenter: David Page
Session: Poster session 15
388P - Anlotinib or bevacizumab combined with chemotherapy for the second-line HER-2 negative metastatic breast cancer: A retrospective cohort study
Presenter: jin xiang
Session: Poster session 15
390P - SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)
Presenter: Maria Cona
Session: Poster session 15
391P - Real-world activity of sacituzumab govitecan for metastatic breast cancer
Presenter: Stefania Morganti
Session: Poster session 15
392P - Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)
Presenter: Adam Brufsky
Session: Poster session 15
393P - A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations
Presenter: Bo Lan
Session: Poster session 15